A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects

Clinical Pharmacology and Therapeutics

Volumn 76, Issue 2, 2004, Pages 128-138

  Raimundo, Sebastian ^a   Toscano, Claudia ^a   Klein, Kathrin ^a   Fischer, Joachim ^a   Griese, Ernst Ulrich ^a   Eichelbaum, Michel ^a   Schwab, Matthias ^a   Zanger, Ulrich M ^a  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; DRUG METABOLIZING ENZYME; SPACER DNA;

ALLELE; ARTICLE; CAUCASIAN; CONTROLLED STUDY; ENZYME ACTIVITY; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENOTYPE PHENOTYPE CORRELATION; HUMAN; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; POPULATION GENETICS; PREDICTION; PRIORITY JOURNAL; PROTEIN FUNCTION; SAMPLE;

ADULT; ANALYSIS OF VARIANCE; BASE SEQUENCE; COHORT STUDIES; CYTOCHROME P-450 CYP2D6; DNA PRIMERS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC SCREENING; GENETICS, POPULATION; GENOTYPE; GERMANY; HUMANS; MALE; MOLECULAR SEQUENCE DATA; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROBABILITY; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC; VARIATION (GENETICS);

EID: 3543014421     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2004.04.009     Document Type: Article

References (26)

1. Meyer U.A. Pharmacogenetics and adverse drug reactions. Lancet. 356:2000;1667-1671
2. Daly A.K. Pharmacogenetics of the major polymorphic metabolizing enzymes. Fundam Clin Pharmacol. 17:2003;27-41
3. Zanger U.M., Raimundo S., Eichelbaum M. Cytochrome P450 2D6 overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol. 369:2004;23-37
4. Bock K.W., Schrenk D., Froster A., Griese E.U., Mörike K., Brockmeier D., et al. The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine and paracetamol as probes. Pharmacogenetics. 4:1994;209-218
5. Griese E.U., Zanger U.M., Brudermanns U., Gaedigk A., Mikus G., Morike K., et al. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics. 8:1998;15-26
6. Ingelman-Sundberg M. Duplication, multiduplication, and amplification of genes encoding drug-metabolizing enzymes evolutionary, toxicological, and clinical pharmacological aspects. Drug Metab Rev. 31:1999;449-459
7. Sachse C., Brockmöller J., Bauer S., Roots I. Cytochrome P450 2D6 variants in a Caucasian population allele frequencies and phenotypic consequences. Am J Hum Genet. 60:1997;284-295
8. Chou W.H., Yan F.X., Robbins-Weilert D.K., Ryder T.B., Liu W.W., Perbost C., et al. Comparison of two CYP2D6 genotyping methods and assessment of genotype-phenotype relationships. Clin Chem. 49:2003;542-551
9. Ingelman-Sundberg M, Daly AK, Nebert DW. Human Cytochrome P450 (CYP) Allele Nomenclature Committee Web site. Available from: URL: http://www.imm.ki.se/CYPalleles/. Accessed June 28, 2004
10. Johansson I., Lundqvist E., Bertilsson L., Dahl M.L., Sjoqvist F., Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci U S A. 90:1993;11825-11829
11. Raimundo S., Fischer J., Eichelbaum M., Griese E.U., Schwab M., Zanger U.M. Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6. Pharmacogenetics. 10:2000;577-581
12. Zanger U.M., Fischer J., Raimundo S., Stuven T., Evert B.O., Schwab M., et al. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics. 11:2001;573-585
13. Dalen P., Dahl M.L., Ruiz M.L., Nordin J., Bertilsson L. 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther. 63:1998;444-452
14. Rau T., Heide R., Bergmann K., Wuttke H., Werner U., Feifel N., et al. Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment. Pharmacogenetics. 12:2002;465-472
15. Barclay M.L., Sawyers S.M., Begg E.J., Zhang M., Roberts R.L., Kennedy M.A., et al. Correlation of CYP2D6 genotype with perhexiline phenotypic metabolizer status. Pharmacogenetics. 13:2003;627-632
16. Osikowska-Evers B.A., Eichelbaum M. A sensitive capillary GC assay for the determination of sparteine oxidation products in microsomal fractions of human liver. Life Sci. 38:1986;1775-1782
17. Kimura S., Umeno M., Skoda R.C., Meyer U.A., Gonzalez F.J. The human debrisoquine 4-hydroxylase (CYP2D) locus sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am J Hum Genet. 45:1989;889-904
18. Steen V.M., Molven A., Aarskog N.K., Gulbrandsen A.K. Homologous unequal cross-over involving a 2.8 kb direct repeat as a mechanism for the generation of allelic variants of human cytochrome P450 CYP2D6 gene. Hum Mol Genet. 4:1995;2251-2257
19. Heim M.H., Meyer U.A. Evolution of a highly polymorphic human cytochrome P450 gene cluster CYP2D6. Genomics. 14:1992;49-58
20. Schaeffeler E., Schwab M., Eichelbaum M., Zanger U.M. CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-time PCR. Hum Mutat. 22:2003;476-485
21. Lovlie R., Daly A.K., Matre G.E., Molven A., Steen V.M. Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype a role for the CYP2D6*35 allele in ultrarapid metabolism? Pharmacogenetics. 11:2001;45-55
22. Idle J.R., Corchero J., Gonzalez F.J. Medical implications of HGP's sequence of chromosome 22 [letter]. Lancet. 355:2000;319
23. Gaedigk A., Ryder D.L., Bradford L.D., Leeder J.S. CYP2D6 poor metabolizer status can be ruled out by a single genotyping assay for the -1584G promoter polymorphism. Clin Chem. 49:2003;1008-1011
24. Yu A., Kneller B.M., Rettie A.E., Haining R.L. Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms. J Pharmacol Exp Ther. 303:2002;1291-1300
25. Allorge D., Harlow J., Boulet O., Hayhurst G.P., Chowdry J., Roth E., et al. In-vitro analysis of the contribution of CYP2D6.35 to ultra-rapid metabolism. Pharmacogenetics. 11:2001;739-741
26. Marez D., Legrand M., Sabbagh N., Guidice J.M., Spire C., Lafitte J.J., et al. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics. 7:1997;193-202